EA202192202A1 - Способы и композиции для лечения синдрома обструктивного апноэ, возникающего во сне - Google Patents
Способы и композиции для лечения синдрома обструктивного апноэ, возникающего во снеInfo
- Publication number
- EA202192202A1 EA202192202A1 EA202192202A EA202192202A EA202192202A1 EA 202192202 A1 EA202192202 A1 EA 202192202A1 EA 202192202 A EA202192202 A EA 202192202A EA 202192202 A EA202192202 A EA 202192202A EA 202192202 A1 EA202192202 A1 EA 202192202A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compositions
- methods
- sleep
- treatment
- apnea syndrome
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000000414 obstructive effect Effects 0.000 title 1
- 201000002859 sleep apnea Diseases 0.000 title 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 abstract 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 abstract 2
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 abstract 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 abstract 1
- 206010041235 Snoring Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000000147 hypnotic effect Effects 0.000 abstract 1
- 229940125425 inverse agonist Drugs 0.000 abstract 1
- 239000003158 myorelaxant agent Substances 0.000 abstract 1
- 208000001797 obstructive sleep apnea Diseases 0.000 abstract 1
- 230000002040 relaxant effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962803223P | 2019-02-08 | 2019-02-08 | |
| PCT/US2020/017323 WO2020163785A1 (en) | 2019-02-08 | 2020-02-07 | Methods and compositions for treating sleep apnea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202192202A1 true EA202192202A1 (ru) | 2021-11-03 |
Family
ID=71947080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202192202A EA202192202A1 (ru) | 2019-02-08 | 2020-02-07 | Способы и композиции для лечения синдрома обструктивного апноэ, возникающего во сне |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12558327B2 (enExample) |
| EP (2) | EP4635514A3 (enExample) |
| JP (2) | JP7705348B2 (enExample) |
| KR (2) | KR102980795B1 (enExample) |
| CN (2) | CN118557736A (enExample) |
| AU (2) | AU2020219809B2 (enExample) |
| BR (1) | BR112021015600A2 (enExample) |
| CA (1) | CA3129270A1 (enExample) |
| EA (1) | EA202192202A1 (enExample) |
| ES (1) | ES3049086T3 (enExample) |
| IL (1) | IL285197A (enExample) |
| MX (2) | MX2021009407A (enExample) |
| MY (1) | MY210043A (enExample) |
| PH (1) | PH12021551850A1 (enExample) |
| SG (1) | SG11202108225QA (enExample) |
| UA (1) | UA130366C2 (enExample) |
| WO (1) | WO2020163785A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111670050A (zh) | 2018-01-30 | 2020-09-15 | 爱普宁公司(特拉华) | 用于治疗睡眠呼吸暂停的方法和组合物 |
| ES3049086T3 (en) | 2019-02-08 | 2025-12-12 | Brigham & Womens Hospital Inc | Methods and compositions for treating sleep apnea |
| IL307186A (en) * | 2021-03-24 | 2023-11-01 | Apnimed Inc Delaware | Methods and preparations for treating sleep apnea |
| JP2024523876A (ja) * | 2021-06-17 | 2024-07-02 | アプニメッド，インコーポレイテッド（デラウェア） | 睡眠時無呼吸を治療するためのノルエピネフリン再取り込み阻害剤 |
| EP4522149A1 (en) * | 2022-05-13 | 2025-03-19 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| CN119789855A (zh) * | 2022-09-02 | 2025-04-08 | 爱普宁公司(特拉华) | 治疗睡眠呼吸暂停的方法和组合物 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| AU767877B2 (en) | 1999-05-20 | 2003-11-27 | Sepracor, Inc. | Methods for treatment of asthma using S-oxybutynin |
| WO2001062236A2 (en) | 2000-02-24 | 2001-08-30 | Pharmacia & Upjohn Company | New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent |
| WO2002089843A1 (en) | 2001-03-13 | 2002-11-14 | Millenium Pharmaceuticals, Inc. | Methods for treating or preventing cardiovascular disorders by modulating metalloprotease function |
| US20030185882A1 (en) | 2001-11-06 | 2003-10-02 | Vergez Juan A. | Pharmaceutical compositions containing oxybutynin |
| US20040235925A1 (en) | 2002-12-17 | 2004-11-25 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| CA2566154A1 (en) | 2004-05-27 | 2005-12-08 | Warner-Lambert Company Llc | Combination of atomoxetine and a 5t1a receptor agonist for treating adhd and other disorders |
| WO2006023703A2 (en) | 2004-08-20 | 2006-03-02 | Cypress Bioscience, Inc. | Method for treating sleep related breathing disorders |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| US20060122127A1 (en) * | 2004-11-17 | 2006-06-08 | Cypress Bioscience, Inc. | Methods for reducing the side effects associated with mirtzapine treatment |
| JP2008524332A (ja) | 2004-12-20 | 2008-07-10 | コレジウム ファーマシューティカル， インク． | 睡眠傷害のための医薬組成物 |
| FR2889811B1 (fr) * | 2005-08-19 | 2009-10-09 | Sanofi Aventis Sa | Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique. |
| DK2083811T3 (en) | 2006-11-22 | 2017-01-30 | Clinical Res Ass Llc | PROCEDURES FOR TREATING DOWNS SYNDROME, FRAGILT X SYNDROME AND AUTISM |
| WO2008122019A1 (en) | 2007-04-02 | 2008-10-09 | Cypress Biosciences, Inc. | Improving the tolerability of both mirtazapine and reboxetine by using them in combination |
| AU2008236624A1 (en) * | 2007-04-09 | 2008-10-16 | Sepracor Inc. | Methods and compositions comprising desvenlafaxine or duloxetine for treating sleep-related breathing disorders |
| WO2008157094A1 (en) * | 2007-06-13 | 2008-12-24 | Cypress Bioscience, Inc. | Improving the tolerability of mirtazapine and a second active by using them in combination |
| BRPI0821761A2 (pt) * | 2007-12-21 | 2015-06-16 | Eurand Inc | Composições de comprimidos de desintegração oral de temazepam |
| US20100204058A1 (en) | 2009-01-28 | 2010-08-12 | Howard Yuan-Hao Chang | Profiling for Determination of Response to Treatment for Inflammatory Disease |
| CN107007602A (zh) | 2011-01-28 | 2017-08-04 | 辉达斯医学研究所 | 治疗阻塞性睡眠呼吸暂停的方法 |
| TWI621434B (zh) | 2014-10-24 | 2018-04-21 | 朗齊生物醫學股份有限公司 | 千憂解藥物應用於癌症治療 |
| HUE047169T2 (hu) | 2015-04-27 | 2020-04-28 | Arena Pharm Inc | 5-HT2C receptor agonisták és készítmények és felhasználási eljárások |
| JP2018516992A (ja) | 2015-06-12 | 2018-06-28 | アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ | レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体 |
| ES2925951T3 (es) * | 2015-07-22 | 2022-10-20 | John Hsu | Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso |
| CN119185558A (zh) | 2017-04-28 | 2024-12-27 | 布里格姆妇女医院 | 用于治疗睡眠呼吸暂停的方法和组合物 |
| CN111670050A (zh) | 2018-01-30 | 2020-09-15 | 爱普宁公司(特拉华) | 用于治疗睡眠呼吸暂停的方法和组合物 |
| ES3049086T3 (en) | 2019-02-08 | 2025-12-12 | Brigham & Womens Hospital Inc | Methods and compositions for treating sleep apnea |
-
2020
- 2020-02-07 ES ES20752195T patent/ES3049086T3/es active Active
- 2020-02-07 EP EP25200289.4A patent/EP4635514A3/en active Pending
- 2020-02-07 CA CA3129270A patent/CA3129270A1/en active Pending
- 2020-02-07 CN CN202410525932.1A patent/CN118557736A/zh active Pending
- 2020-02-07 KR KR1020217027063A patent/KR102980795B1/ko active Active
- 2020-02-07 WO PCT/US2020/017323 patent/WO2020163785A1/en not_active Ceased
- 2020-02-07 MX MX2021009407A patent/MX2021009407A/es unknown
- 2020-02-07 US US17/428,596 patent/US12558327B2/en active Active
- 2020-02-07 EA EA202192202A patent/EA202192202A1/ru unknown
- 2020-02-07 CN CN202080026282.6A patent/CN113692277B/zh active Active
- 2020-02-07 PH PH1/2021/551850A patent/PH12021551850A1/en unknown
- 2020-02-07 SG SG11202108225QA patent/SG11202108225QA/en unknown
- 2020-02-07 EP EP20752195.6A patent/EP3920898B1/en active Active
- 2020-02-07 MY MYPI2021004502A patent/MY210043A/en unknown
- 2020-02-07 JP JP2021546285A patent/JP7705348B2/ja active Active
- 2020-02-07 UA UAA202104441A patent/UA130366C2/uk unknown
- 2020-02-07 BR BR112021015600-3A patent/BR112021015600A2/pt unknown
- 2020-02-07 KR KR1020267019432A patent/KR20260103155A/ko active Pending
- 2020-02-07 AU AU2020219809A patent/AU2020219809B2/en active Active
-
2021
- 2021-07-28 IL IL285197A patent/IL285197A/en unknown
- 2021-08-04 MX MX2025004365A patent/MX2025004365A/es unknown
-
2025
- 2025-02-03 JP JP2025016270A patent/JP2025084754A/ja active Pending
- 2025-07-15 AU AU2025205464A patent/AU2025205464A1/en active Pending
-
2026
- 2026-01-23 US US19/457,930 patent/US20260151361A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118557736A (zh) | 2024-08-30 |
| CN113692277B (zh) | 2024-07-16 |
| MX2021009407A (es) | 2021-09-10 |
| ES3049086T3 (en) | 2025-12-12 |
| SG11202108225QA (en) | 2021-08-30 |
| PH12021551850A1 (en) | 2022-05-11 |
| EP3920898A4 (en) | 2022-11-09 |
| KR102980795B1 (ko) | 2026-06-23 |
| AU2020219809B2 (en) | 2025-04-17 |
| WO2020163785A1 (en) | 2020-08-13 |
| BR112021015600A2 (pt) | 2021-10-05 |
| US12558327B2 (en) | 2026-02-24 |
| JP2025084754A (ja) | 2025-06-03 |
| EP3920898C0 (en) | 2025-09-10 |
| EP4635514A2 (en) | 2025-10-22 |
| UA130366C2 (uk) | 2026-02-04 |
| KR20210125507A (ko) | 2021-10-18 |
| EP4635514A3 (en) | 2025-12-24 |
| JP7705348B2 (ja) | 2025-07-09 |
| CN113692277A (zh) | 2021-11-23 |
| EP3920898B1 (en) | 2025-09-10 |
| US20220096401A1 (en) | 2022-03-31 |
| KR20260103155A (ko) | 2026-07-02 |
| AU2025205464A1 (en) | 2025-07-31 |
| IL285197A (en) | 2021-09-30 |
| US20260151361A1 (en) | 2026-06-04 |
| EP3920898A1 (en) | 2021-12-15 |
| MY210043A (en) | 2025-08-22 |
| AU2020219809A1 (en) | 2021-08-19 |
| JP2022519721A (ja) | 2022-03-24 |
| MX2025004365A (es) | 2025-05-02 |
| CA3129270A1 (en) | 2020-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502427A1 (en) | Methods and compositions for treating sleep apnea | |
| MX2025004365A (es) | Metodos y composiciones para el tratamiento de la apnea del sue?o | |
| JOP20220284A1 (ar) | إيميدازوبيريدازين في صورة مُعدِلات il-17 | |
| CR10342A (es) | INHIBIDORES DE LOS CANALES DE IONES TASK-1 y TASK-3 | |
| MX2015012760A (es) | Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma. | |
| HUE068505T2 (hu) | Eljárások és készítmények alvási légzésszünet vagy az egyszerû horkolás kezelésére | |
| JOP20240059A1 (ar) | المركبات المثبطة إيميدازوبيريدازين il-17 | |
| WO2007105113A3 (en) | Use of crf1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia | |
| MX2019007378A (es) | Formas de administracion farmaceutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios. | |
| PH12019501458A1 (en) | Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy | |
| MX2021003428A (es) | Antagonistas del receptor adrenérgico a2 subtipo c (alfa-2c) para el tratamiento de la apnea del sueño. | |
| WO2016025671A3 (en) | Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist | |
| CR20210420A (es) | Composiciones farmacéuticas que comprenden meloxicam | |
| EA201992569A1 (ru) | Способы и композиции для лечения апноэ во сне | |
| EA202092979A1 (ru) | Способ лечения обратным агонистом гистаминового рецептора 3 типа | |
| MX2023011213A (es) | Métodos y composiciones para tratar la apnea del sueño. | |
| MX2024007768A (es) | Combinacion de un antagonista de adrenoreceptor a2 subtipo c (alfa-2c) con un inhibidor de recaptacion de norepinefrina para el tratamiento de apnea del sue?o. | |
| JOP20210113A1 (ar) | مناهضات لمستقبلات ألفا 2 الأدرينالية من النمط الثانوي سي (ألفا-2سي) لمعالجة انقطاع النفس أثناء النوم | |
| EA201990341A1 (ru) | Замещенные диазагетеробициклические соединения и их применение | |
| EA201991538A1 (ru) | Фармацевтические лекарственные формы, содержащие ингибиторы каналов task-1 и task-3, и их применение для лечения нарушений дыхания | |
| HK40041686A (en) | Compositions and methods for treating obstructive sleep apnea | |
| EA201991540A1 (ru) | Фармацевтические лекарственные формы, содержащие ингибиторы каналов task-1 и task-3 и их применение для лечения нарушений дыхания |